Context: Whether natural product drug discovery programs should rely on wild plants collected "randomly" from the natural environment, or whether they should also include plants collected on the basis of use in traditional medicine remains an open question.
Introduction
One of the persistent questions in natural product drug discovery has been whether testing plants on the basis of their use for specific diseases in traditional medicine would lead to a higher rate of discovering active lead compounds than simply testing plants "randomly" from the natural environment, ie., opportunistically collecting whatever plants are available without regard to traditional use (Farnsworth, 1994) . For example, Rios and Recio (2005) suggest that random selection of plants be avoided in the search for new antimicrobials, and that plants collected on the basis of ethnopharmacological information be emphasized. Accordingly, Svetaz et al. (2010) assayed plant species with a history of medicinal uses from Latin America for bioactivity against fungal pathogens, and discovered that plants with ethnomedical (e.g. traditional medicine) uses were significantly more likely to inhibit growth of pathogenic fungi than randomly collected plants (40% vs 21%). Coelho de Souza et al. (2004) , however, found little correlation of traditional use and activity of plants in antibacterial assays. Cragg et al. (2009) list some anticancer drugs and lead compounds discovered based upon traditional medicine use. Spjut (2005) found that plants used as anthelmintics and arrow poisons had a higher percentage activity than plants assessed randomly in the National Cancer Institute records of plants screened against cancer (cancer cell cytotoxicity is thought to be one of the areas poorly targeted by ethnomedical use because of the poor definition of cancer signs, symptoms and disease concepts in traditional medicine). If ethnomedical information is significantly correlated with activity against such drug development targets, it is hypothesized that the number of plants that would need to be collected and evaluated in order to discover a successful natural product drug could be significantly reduced. This would lead to financial savings and efficiencies in research.
Further data on this question are thus needed.
The Vietnam-Laos International Cooperative Biodiversity Group (ICBG) project "Studies of Biodiversity of Vietnam and Laos" has operated since 1998 with funding from the Fogarty International Center of the U.S. National Institutes of Health. It has been described in detail elsewhere (Soejarto et al. 1999 (Soejarto et al. , 2002 (Soejarto et al. , 2004a (Soejarto et al. , 2007 . Ninh Binh Province of Vietnam. The availability of data on both ethnomedical and random plant collections made by a single project and analyzed using the same bioassay techniques gives us the opportunity to test the hypothesis that plants collected on the basis of ethnomedical use will result in a higher hit rate, or percentage of plants active in bioassays, than plants collected randomly. It also allows us to assess the corollary proposition that drug development assays will confirm the supposed clinical activity of the traditional medicine plants.
Methods

Ethnobotany-guided plant collections
To collect plants with ethnomedical information, interviews with traditional healers in Laos and Vietnam were conducted, and the plants they listed as being used for different diseases were collected from nearby field sites. Interviews were conducted chiefly by project staff at the Vietnam and Lao collaborating institutions, who received training based on questionnaires and interview methods developed by UIC project coordination staff.
The plants in Laos were collected in collaboration with the Institute of Traditional Medicine (ITM, formerly the Traditional Medicine Research Center) in Vientiane. The Laos collection process is described in detail elsewhere in this issue (Soejarto et al. 20XX) . The ITM maintains a network of Traditional Medicine Stations throughout Laos (Soejarto et al., 1999 Riley 2001) 1997-1056 and # 2003-0636, #2003-0217, 2004-0197 and # 2007-0369 . Prior informed consent was sought at ministerial, provincial and local levels for the project, and individual informed consent was obtained before commencing interviews. The project also is governed by a comprehensive benefit-sharing agreement in order to comply with the Convention on Biodiversity. For most plants, multiple uses were recorded. In addition to recording traditional medicine uses of each plant species, project staff collected both herbarium specimens used to identify the plant species and serve as a permanent record of the plants collected, together with bulk samples of plant material (e.g. 0.5 kg dry weight) to be used for extraction and bioassay testing. In most cases, only the plant parts mentioned as being useful by the healers were collected.
Biodiversity-based ["random"] collection
Plants for the "random" or biodiversity-maximized collection were obtained in Cuc Phuong National Park, in collaboration with Park scientific staff. Cuc Phuong National Park was inaugurated in 1962. It is located in a limestone karst area of the Annamite Mountains, and has a nearly 600 m elevational range. More than 2000 vascular plant species are found in the park (Soejarto et al. 2004b) , reflecting the large number of available environments. Several areas in the park were inhabited by Muong minority communities until the late 1980s, but following government-sponsored relocation program in the 1990's, all Muong households are now settled in areas surrounding the Park, and the areas impacted by them is minor. The goal of the ICBG collection was to obtain as high a biodiversity of plant species as possible. Thus, in the field collection process, plant species that had already been collected or for which we had already collected multiple species in the same genus were avoided. This collection is referred to in the current paper as a random collection since it was gathered without regard to traditional medicine use; it does not constitute a true random sample of Park vegetation, but is nonetheless consistent with typical collection practices in the drug discovery field.
In the field collection process, both herbarium specimens (and bulk samples of plant parts were collected from a single individual plant. Typically multiple plant parts were collected as bulk samples for each species. For both the ethnomedical and the random collections, herbarium specimens were deposited at the herbaria of Cuc Phuong National Park (CPNP) and the Institute of Ecology and Biological Resources of the Vietnam Academy of Science and Technology in Hanoi (HN) in Vietnam, and at the herbarium of the Institute of Traditional Medicine in Vientiane in Laos, as well as at the Field Museum (F) in Chicago. Taxonomic identification was performed at these institutions, as well as with the assistance of taxonomic specialists in some cases. For the present analysis, only plant collections that were identified to species level, or at least to genus, were included in order to avoid undetected duplication of species collected due to unidentified specimens.
Post-collection processing and data management
Following the field interviews and collections, all bulk plant samples were dried and extracted according to ICBG project's extraction protocols. They were then subjected to a variety of bioassays at the UIC and VAST laboratories of the ICBG program, as well as at the Pasteur Institute in Hanoi (antimycobacterial assay), Purdue University (cancer chemoprevention assay). Each sample was tested in multiple bioassays for an average of approximately 7 bioassays per plant sample. Based on these bioassays, bioactive compounds have been isolated and their chemical structures and modes of action have been published (Soejarto et al., 20xx, this issue) 
Plant collections and plant samples
Accessions were analyzed at the level of collections (a single plant species collected in one locality at one time) and samples (a single plant part or a set of pooled parts from a collection; collections could have more than one plant part sampled, e.g. fruits, seeds, leaves plus stems, or other parts). Figure 1 shows graphically the difference between plant collections and plant samples, as well as the eventual destination of the voucher specimens that represent each collection, and the bulk samples for laboratory analysis.
We distinguish collections versus samples to help clarify the different aspects of effort in obtaining and processing plant materials for drug discovery screening projects. In the process of collection, whether ethnomedical or random, two types materials were gathered, and prepared from one single individual plant: a) voucher herbarium specimens (a series of 3-7 specimens) intended for taxonomic identification and other botanical studies; b) one or more bulk samples each consisting of one plant part or a combination of parts, f.e., leaf plus twigs, stem bark, or root, ,in the amount of approximately 1000 g fresh weight (≈ 400 g dry), intended for bioassay and chemical analysis. The two plant materials are linked by a common identifier, normally the name and number of the collector. The destination of voucher herbarium specimens is a Herbarium institution, where taxonomic identification is performed, whereas the destination of the bulk samples is the laboratory, where the samples are extracted, then the extract submitted to biological assay, which may be followed by bioassay-guided fractionation, in the event of active extracts. involved the location of an appropriate individual of a plant species, obtaining ethnomedical information if necessary, collecting voucher specimens and procuring botanical identification. On the other hand, each sample represented a separate effort in the bulk collection, extraction, bioassay test (s) and, where appropriate, fractionation. Thus, the collections were considered to relate more to the effort of field acquisition whereas the samples relate more to the effort of laboratory analyses.
[ Figure 1 about here] Accessions were further analyzed by plant uses. The basic data point for a plant use stored in NAPIS is an excerpt from the field interview, usually a description of a disease or symptom for which the plant is used, such as cough, malaria, stomach-ache, diabetes or other condition. Because of the diversity of such descriptions, for this analysis we assigned a further data element, ethnomedical use category. These categories were assigned based on groups of use descriptions that were potentially relevant to the bioassay targets of the overall project. Twelve use categories were developed: bacterial, cancer, cardiovascular, central nervous system (CNS), infection, inflammation, malaria, miscellaneous, parasite, tuberculosis (TB) and viral. Uses describing a symptom or disease that characterizes one of these use categories were assigned to that category.
Thus, malaria, fever and chronic fever are assigned to the malaria ethnomedical use category. Tuberculosis, cough, fatigue and lung disease are assigned to the tuberculosis ethnomedical use category. Hepatitis, dengue fever, measles and other viral diseases are assigned to the viral category. Diabetes, stomach-aches, folk illnesses and a number of other common complaints that did not appear to fit well into mechanisms relevant to the project's bioassay targets were assigned to the miscellaneous category.
The ethnomedical use categories were related to the bioassay targets of the study on a mechanistic basis. The malaria use category could be related to antiplasmodial assays.
The bacterial, parasitic and TB categories could be related to the antimycobacterial assays. The viral category, in contrast to the TB and malaria categories, included multiple common viral diseases. This was thought to be related to HIV assays to the extent that plants used for viral diseases might show some general antiviral activity. There were very few attributions of use for HIV specifically by our informants. Cancer prevention could be related to the inflammation and cancer categories; no concept of cancer prevention was encountered among our informants, but inflammation is thought to be strongly related to carcinogenesis (Tan et al. 2011) . The relationship of plants in the cancer category is also questionable since cancer is not a common disease in rural populations of Laos and Vietnam.
Statistical analysis
Data were analyzed using contingency tables and percentage calculations of hit rate or positive activity based on qualitative bioassay results of "A". Statistical significance was tested for the contingency tables, using chi square analysis, or, for tables with small numbers of samples, Fisher's exact test (the latter does not yield a chi-square statistic as will be seen in the tables below). We used an alpha of p=0.05. However, because we performed multiple statistical tests, we used the Bonferroni correction for multiple comparisons, resulting in a significant p-value for this study of .00135.
For the initial analyses we grouped bioassay results at the levels of collections (a species collected on a certain date from a particular locality) and samples (plant parts) to determine if ethnomedical collections or samples had a higher hit rate (percentage "A" qualitative result in bioassay) than random samples or collections. As a followup assessment, we tested whether the plants with an ethnomedical use category that is directly related to the assay target had a higher hit rate than plants in other ethnomedical use categories or than random accessions. In investigating the results from this assay, we also plotted proportional frequency graphs for different groups of ethnomedical plant accessions (Laos vs Vietnam) and different bioassays, to see if the distribution of use categories differed.
Bioassay results were grouped as follows: for collections level analyses, a single qualitative was assigned to a collection based on the best qualitative result for any sample or test arising from that collection, with active ranked as the best, questionable in the middle, and inactive as the worst result (A>Q>I). Thus, in an assessment of any single bioassay or group of bioassays, if any sample tested for one collection has a qualitative result of A, that collection is assigned the value of A for that bioassay. If none was active but one or more were questionable, the collection is assigned a value of Q. If no samples were active or questionable, the collection is assigned a value of I. A similar procedure is used to assign a qualitative result to a sample when sample groupings are tested.
For tuberculosis and HIV we used only a single bioassay each, so qualitative results refer only to these test results. For the target diseases in which we used multiple bioassays ( antiplasmodial, cancer chemoprevention and cancer treatment), we assessed activity based on both individual bioassays and the entire group of bioassays for the target conditions.
[ versus random samples) were tested.
Results
The results of the overall assessment of whether all ethnomedical collections and samples had a higher hit rate than all random collections and samples are summarized in Table 3 .
[ Table 3 about here]
The results of the contingency table analysis and the hit rates indicate a contrasting situation between the collections analysis and the samples analysis. For both collections and samples the results are highly significant. However, in the case of collections, the random collections have a somewhat higher hit rate (31% vs 28.5%) whereas for the samples, the ethnomedical samples have a higher hit rate (28.1% vs 22.2%).
[ Table 4 about here] with ethnomedical rationale than random collections. For the malaria, HIV and cancer treatment, the random collections had a higher hit rate than the ethnomedical collections.
The hit rate for the Vietnam ethnomedical collections appears to be lower than that for the Laos collections in tuberculosis and cancer treatment bioassays.
[ Table 5 about here] Antiplasmodial activity and cancer chemoprevention are non-significant. In the case of antiplasmodial assays, the hit rates of the samples collected with different rationales are quite similar, though this is not the case with cancer chemoprevention. In the case of the samples, the bioassay results indicate that for antimycobactetrial and cancer the hit rates favor ethnomedical samples, specifically the samples from Laos. For HIV the hit rates favor random samples, though the difference is quite small.
[ Table 6 about here] HIV assays, because there was only one bioassay for each of these targets, the results are the same as in Table 5 . For antiplasmodial activity, the results of the two assays, D6 and W2, are notably different. For D6, the chi-square is non-significant, and the hit rates are similar for all accession types. For W2, however, the chi-square is significant, and the hit rate is much higher than for the D6 assay. D6 was used as the primary screen for these samples, while W2 was used primarily but not exclusively as a confirmatory screen, so that samples that had been active in the D6 assay were submitted to the W2 assay as a secondary screen. Additionally, W2 has been observed to be more sensitive than D6 (Yuan et al. 2009 ). Another feature of the W2 assay is that the hit rate of the ethnomedical samples (75-80%) is much higher than the hit rate of the random samples (45%). In the case of cancer chemoprevention, none of the contingency tables was significant, while in the case of cancer treatment, only HL-60 and LNCaP were significant, but the percentage differences in hit rates were quite small. In tuberculosis and cancer assays, we again see the plants of Vietnam with a lower hit rate than those of Laos or the random plants.
[ Table 7 about here] One possible reason for the difference in the antimycobacterial assays is that they were performed in two different laboratories, one at UIC and one in Hanoi. While there are other possible explanations that are somewhat speculative, an explanation that could be addressed using our dataset is whether the types of ethnomedical uses for plants collected in Vietnam and Laos were similar or different.
[ Figure 2 about here] [ Figure 3 about here]
To explore the question of the most active use categories, we created similar frequency graphs, shown in Fig. 3 , for each of the project's disease targets. These graphs show the frequencies of ethnomedical use categories for the collections that were found to be active in each of the assay systems, charted alongside the frequencies of ethnomedical use categories in the total collection (the same data as for the total collection as shown in Fig. 2 ). These charts may suggest which ethnomedical use categories were actually the most likely to be active in the five bioassay targets.
Inspecting Fig. 3A , it can be observed that while the frequency of active plants in the use category of tuberculosis (n=33) was higher than the frequency of plants used for tuberculosis in the entire collection, the use category that was by far the most likely to be active was central nervous system plants, although this sample size is rather small. The active central nervous system plants had ethnomedical uses of nervine, tonic and pain.
Among the plants active in the malaria bioassays (Fig. 3B, n=112) , most use categories, including malaria, occurred at about the same frequency as the total collection, with the exception of plants used for viral disease and to a smaller extent, central nervous system uses, which were more frequent that would be expected in the total collection. In the plants active in the HIV bioassay (Fig. 3C, n=19 ), plants used for malaria and cancer occurred more frequently than in the total collection, although this sample size was also rather small. Among plants active in the chemoprevention bioassays (Fig. 3D, n=246) , plants in the cardiovascular, miscellaneous, parasite and viral groups occurred more frequently than in the total collection. Among plants active in the cancer treatment bioassays (Fig. 3E, n=284) , plants in the cancer, malaria and miscellaneous groups occurred more frequently than in the total collection.
Discussion
These results cast some light on the questions of whether testing of traditional medicine plants may result in a higher hit rate in drug discovery programs than testing plants collected without regard to traditional medicine use, and whether drug discovery bioassays may support the supposed clinical uses of traditional medicine plants. Table 3 showed contradictory results. When analyzed according to collections, random plants were about 3 percentage points more likely to result in at least one active bioassay among all the test results. When analyzed according to samples (plant parts), the ethnomedical plants were about 6 percentage points more likely to result in at least one active bioassay.
This could simply reflect the situation that random plants had more plant parts collected than ethnomedical samples. With more samples, and thus more test results, contributing to the possibility of a single plant collection receiving an "active" designation, the random collections likely had a greater probability of being active than the ethnomedical collections, which usually had only one plant part tested. Thus, it is likely that the ethnomedical collections actually had a higher hit rate on a per sample basis than the randomly collected species. But how did the ethnomedical uses actually correlate with the bioassay results? To address this question each of the main disease targets is discussed separately.
Tuberculosis
In the case of tuberculosis, both the analysis by collections and the analysis by samples had higher hit rates than the random accessions. This indicates that ethnomedical sampling did accurately predict antimycobacterial activity. However, Table 7 and Fig. 3A suggest that the ethnomedical use of plants for tuberculosis did not predict positive bioassay results that well. Among the plants that were in the ethnomedical use category of "tuberculosis," only five were actually active in the MABA-H37RA bioassay; the specific uses attributed to them were cough in 4 cases and fatigue in one case. The ethnomedical category that was clearly the most active in this bioassay was "central nervous system," composed of uses such as nervine, tonic and pain.
For the most part, these central nervous system species did not have other uses attributed to them, i.e., they were not additionally used for tuberculosis, infections or other conditions. The elevated rate of activity among these central nervous system plants could simply reflect a random variability in this rather small sample, and be unrelated to the use of the plants. One could also speculate that such plants were being used as tonics to address the fatigue common among tuberculosis patients, but actually or additionally were acting against the tuberculosis bacillus.
Malaria
For the antiplasmodial assays, the random plants clearly had a higher hit rate when assessed at the level of collections (species) but not when addressed at the level of samples. In the assessment of the W6 confirmatory bioassay, the ethnomedical plants had a significantly and obviously higher hit rate than the random plants. This suggests that the antiplasmodial activity was more robust in the ethnomedical plants than in the random plants, and that they might thus be better sources of active compounds. This may suggest confirmation of the ethnomedical application of these plants. Plants classified in the ethnomedical use category of malaria (used for malaria, fever, etc), however, were not over-represented among active plants in the antiplasmodial assays (Fig. 3B ) -plants used for viruses and central nervous system uses were more likely to be active.
HIV
In the case of HIV bioassays, random accessions were more likely than ethnomedical accessions to be active both at the collections level and at the samples level. The plants that were most likely to be active in this assay were used for cancer, malaria and parasites (Fig. 3C) ; however, the number of ethnomedical samples that were active against HIV is quite small (n=19) and this may represent a random fluctuation. A complication in relating plants in the viral ethnomedical use category to anti-HIV bioassays is the fact that HIV is a retrovirus, unlike the causative agents of the common viral diseases that were most often encountered in our ethnomedical data.
Cancer chemoprevention
In the case of the cancer chemoprevention bioassays, the contingency tables were not significant for either collections or samples. The plants that were most likely to be active in this bioassay were those used for cardiovascular, miscellaneous, parasite and viral use categories. This was a large sample, but the differences between the uses of the active accessions and the total collection were not that marked in any of these instances, making discussion of possible mechanisms rather speculative.
Cancer treatment
In the case of cancer treatment bioassays (cancer cell culture lines), the contingency tables were significant for both the collections and samples. In both cases, the hit rates favored the random plants over the Laos ethnomedical plants, but part of the significance of the tables may have been due to the low hit rate of the Vietnam ethnomedical plants. The categories most likely to have been active in this assay were cancer, malaria and miscellaneous plants. Thus, there may be some rationale for collecting plants traditionally used for cancer to test against cancer cell lines, but, like Spjut (2005) , our data suggest that other uses may be more likely to give positive results.
Laos versus Vietnam results
The 
Support for the ethnomedical hypothesis
As mentioned at the start of this discussion, the analysis of all ethnomedical samples versus all random samples in all bioassays ultimately suggests that ethnomedical samples are indeed more likely to have positive results in drug discovery bioassays. The higher hit rate among all random collections may be attributable at least in part to the larger number of samples analyzed for each random collection than for the ethnomedical collections. This level of support does not appear to extend, however, to the corollary hypothesis that drug discovery bioassays will tend to affirm the mechanisms of specific ethnomedical uses of plants. A higher hit rate in the W6 confirmatory bioassay for malaria does suggest that the ethnomedical plants do have a more antimalarial activity than the randomly collected plants. In only two instances, however, tuberculosis and cancer treatment, were the plants in a specific ethnomedical use category more likely to be among the active species in the bioassays with which they were most obviously correlated. Other ethnomedical use categories that were over-represented among active plants were central nervous system, malaria, viral and miscellaneous. These, however,
were not correlated mechanistically with the assays that corresponded to them. The Another means of evaluating whether plants collected for ethnomedical purposes may contribute to natural product drug discovery programs is to determine whether, in fact, any ethnomedical plants proceeded further along the path towards clinical testing than simply giving positive results in bioassays. Our group has published articles on active compounds from 13 species to date (He et al. 2005 (He et al. , 2006 Jutiviboonsuk et al. 2005; Ma et al. 2005 Ma et al. , 2006 Ma et al. , 2008 Nguyen et al. 2004; Truong et al. 2011 ; Zhang et al. 2002 Zhang et al. , 2003a Zhang et al. , 2003b Zhang et al. , 2004 Zhang et al. , 2006 . Of these, 5 are from plants with ethnomedical uses.
The correlation of active compound activity with ethnomedical use in these papers was not straightforward?. For instance, the species Rourea minor (Gaertn.) Alston (Connaraceae) is used for dengue fever in Laos; the publication by He et al. (2006) presents antiplasmodal compounds isolated from this species. An interesting correlation to be noted is the observation in this paper that antiviral plants were over-represented among the plants active against malaria. Asparagus cochinchinensis (Lour.) Merr.
(Asparagaceae) was recorded to be used in Laos for chronic fever, although uses for fever, cough, kidney disease and benign breast tumors have been recorded from China.
Chronic fever is a symptom that could relate to multiple diseases such as infections these in-progress data are not included in this analysis. In some cases the sample sizes of specific analyses are rather small, and we did perform a large number of analyses on this dataset. However, the dataset itself is quite large (over 24 000 bioassay results form the basis of the calculations), and we have addressed the specific statistical concerns for multiple comparisons and contingency tables with small expected cell sizes.
Nonetheless, some of the results based on small sample sizes should be taken as tentative.
The assignment of symptoms and diseases reported in interviews to ethnomedical use categories may have been subject to inaccuracy, lack of clarity or misunderstanding of culture-bound concepts of disease, leading to uncertainty in the circumscriptions of these categories.
Further, this study cannot address the question of whether ethnomedical plants are actually selected by healers based on experience with their bioactivity, or whether other factors influence their selection. Moerman et al. (1999) note that ethnic groups in the Northern Hemisphere that are widely separated by a history of migrations, but are nevertheless culturally and genetically related, have strikingly similar medicinal floras.
This suggests that cultural influences may affect the selection of herbs, as well as direct experience with their bioactivity. Leonti (2011) 
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